Is Soligenix, Inc. overvalued or undervalued?

As of 13 August 2021, the valuation grade for Soligenix, Inc. has moved from risky to does not qualify, indicating a shift in the assessment of its financial health. The company appears to be overvalued given its current price of $1.65, especially when considering its negative P/E ratio due to being loss-making, a Price to Book Value of 1.74, and an extraordinarily high ROCE of 295.01%, which is not sustainable.
In comparison to its peers, Soligenix's EV to EBITDA stands at 0.09, while Inhibikase Therapeutics, Inc. has a similar valuation grade with an EV to EBITDA of -0.9168, and Aileron Therapeutics, Inc. shows an EV to EBITDA of -1.2239. These comparisons suggest that Soligenix is not only struggling relative to its industry but also lacks the financial metrics to justify its current valuation. Overall, the analysis indicates that Soligenix, Inc. is overvalued in the current market context.